What question did this study set out to answer?

Abstract PS2-04-01: Early Adoption of Molecular Residual Disease Testing in Breast Cancer Patients using Real World Data

View Full Paper

Ask AI

Bookmark

The study aims to evaluate the early adoption of molecular residual disease testing in breast cancer patients using real-world data.
Utilized national multi-payer medical and pharmacy claims data fromSTATinMED RWD Insights.
Focused on female patients aged ≥18 years diagnosed with breast cancer.
Included patients with continuous enrollment for at least 12 months pre- and 30 days post-index.
Identified MRD utilization from the index date to study end or patient death.
Applied multivariate logistic regression to identify predictors of MRD test adoption.
Among 652,463 eligible patients, only 815 (0.12%) underwent MRD testing, primarily in 2023.
Patients received an average of 1.72 MRD tests, with variations in frequency across subtypes.
Key factors affecting MRD testing adoption included younger age, advanced cancer stage, subtype, and residence region.

No takes yet. Share an insight, caveat, or question.

An analysis of MRD testing trends in breast cancer patients, indicating significant early adoption and utilization variances.

Gu et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark